Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2012-12-07

Clinical Trial Update: Safety Study of ALG- 1001 to Treat Diabetic Macular Edema [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 safety trial of ALG-1001 for diabetic macular edema was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALG-1001

Snippet

Sponsor: Allegro Ophthalmics, LLC | Conditions: Diabetic Macular Edema | Phase 1, Phase 2 | Status: WITHDRAWN